{"id":"W2981177537","doi":"10.1016/j.jtho.2019.10.005","title":"A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Royal Victoria Hospital","funders":"Merck Sharp and Dohme; Imclone; Astellas Pharma; Pharmacyclics; Roche España; Cilag; AstraZeneca España; Puma Biotechnology; Daiichi-Sankyo; Celldex Therapeutics; Taiho Pharmaceutical; Halozyme; Luitpold Pharmaceuticals; BioMarin Pharmaceutical; GlaxoSmithKline España; AbbVie; Novartis; Celgene; Alexion Pharmaceuticals; Gilead Sciences; Roche; Exelixis; Kyowa Hakko Kirin; Sanofi; Merck; GlaxoSmithKline; Genentech; Hospira; Boehringer Ingelheim; Amgen; Incyte; Pfizer; Asana Biosciences; AstraZeneca; Boehringer Ingelheim España; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Darbepoetin alfa; Placebo; Anemia; Chemotherapy; Epoetin alfa; Oncology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004327128,0.001378526,0.0027555,0.0004141684,0.0005490371,0.001005373,0.0008783391,0.00174218,0.004024772],"category_scores_gemma":[0.003255936,0.0007151592,0.001741959,0.0003695146,0.001379007,0.0008831069,0.0003639662,0.00302616,0.0006820279],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006651017,"about_ca_system_score_gemma":0.001826846,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004780381,"about_ca_topic_score_gemma":0.001046975,"domain_scores_codex":[0.9984842,0.0009852977,0.00009901376,0.000195182,0.0001277839,0.0001084717],"domain_scores_gemma":[0.997664,0.0007549864,0.0006923845,0.00019903,0.0001747771,0.0005147234],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9752794,0.010059,0.0005044193,0.0004288925,0.0007600869,0.00002087262,0.00004043212,0.0001989936,0.003477842,0.00007012363,0.0003335479,0.008826447],"study_design_scores_gemma":[0.9305234,0.06746666,0.001000145,0.00001471266,0.0002086878,0.0000119456,0.000005330818,0.0001584754,0.0002873545,0.00005380978,0.0002636722,0.000005973348],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9792469,0.004315235,0.001577584,0.0006377503,0.0005793256,0.01092952,0.001010931,0.0001427708,0.001559878],"genre_scores_gemma":[0.9797035,0.00202392,0.00263438,0.001139764,0.0005252089,0.01107782,0.0008150149,0.00002154065,0.002058843],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004327128,"threshold_uncertainty_score":0.02288437,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01797075565422417,"score_gpt":0.3831675726813219,"score_spread":0.3651968170270977,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}